Pertuzumab bulk supplier for pharma manufacturers

Pertuzumab 420 mg/14 mL Suppliers & Bulk Manufacturers

Available Forms: Solution for IV infusion

Available Strengths: 420 mg/14 mL

Reference Brands: Perjeta (USA/EU)

Pertuzumab 420 mg/14 mL concentrate for intravenous infusion, a HER2 monoclonal antibody used with trastuzumab in breast cancer. For oncology importers, distributors and hospital tender buyers.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Pertuzumab? List it or send an offer →

Product Description:

Pertuzumab is a humanised monoclonal antibody against HER2, a growth receptor overexpressed in some breast cancers. It binds the region of HER2 that pairs with other HER receptors, especially HER3, blocking the dimerisation that drives tumour signalling. Trastuzumab binds a different region, so the two are given together for fuller blockade. This page covers 420 mg/14 mL concentrate for intravenous infusion in a single-dose vial, used in oncology day units with a pharmacy able to prepare antibody infusions.

Pertuzumab is combined with trastuzumab and chemotherapy in HER2-positive breast cancer: before surgery in locally advanced, inflammatory or early disease, after surgery in high-risk early disease, and with docetaxel in untreated metastatic disease. HER2 status must be confirmed by a validated test. The schedule is an 840 mg loading dose over 60 minutes, then 420 mg every three weeks. It is diluted in 0.9% sodium chloride, not glucose. Cardiac function is checked during treatment, infusion reactions are watched for, and contraception is required.

Sourcing notes. Pertuzumab is a prescription-only biologic needing an unbroken 2-8 °C cold chain; it must not be frozen and stays in its carton away from light. Ask for temperature loggers on every shipment. Non-reference products are registered in some markets as biosimilars, with far more comparability data than a small-molecule generic, so check the approval route locally. Request the CTD dossier, a CoA per batch, the GMP certificate for biologics, a CoPP and the lot release certificate where the national control laboratory requires one. State vials per pack and remaining shelf life.

Pertuzumab — third party manufacturing & bulk supply

Pertuzumab 420 mg/14 mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Pertuzumab is supplied as Solution for IV infusion — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Pertuzumab listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Pertuzumab →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Pertuzumab is used for the treatment of HER2-positive breast cancer. It is commonly given in combination with trastuzumab and chemotherapy for patients with metastatic breast cancer, as well as in neoadjuvant and adjuvant treatment settings.

Pertuzumab is a humanized monoclonal antibody produced using recombinant DNA technology in mammalian cell cultures. It is designed to specifically target the HER2 receptor on cancer cells.

The primary trade name of Pertuzumab is Perjeta.

Pertuzumab (Perjeta) is developed and marketed by F. Hoffmann-La Roche.

The generic name is Pertuzumab.

The main brand name is Perjeta.

Pertuzumab is manufactured in GMP-certified biologics manufacturing facilities approved by regulatory authorities such as the US FDA, EMA, and other global health agencies depending on the region of supply.